Skip to content

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

News

Select Year
Clinical Trials
Search …

January 25, 2018

Oncolytics Biotech(R) Named to the 2018 OTCQX Best 50

January 19, 2018

Oncolytics Biotech(R) Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas

January 16, 2018

Oncolytics Biotech® Announces Abstract for Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas

December 27, 2017

Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas

December 5, 2017

Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer

December 4, 2017

Oncolytics Biotech® to Present at the Oncolytic Virotherapy Summit

November 30, 2017

Oncolytics Biotech® Establishes Scientific Advisory Board Focused on REOLYSIN® Registration Study in Metastatic Breast Cancer

November 16, 2017

Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®

November 8, 2017

Oncolytics Biotech® Inc. Announces 2017 Third Quarter Results

November 2, 2017

Oncolytics Biotech® Appoints Deborah Brown to Board of Directors

Page 30 of 69

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.ca

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Loading...

4350 Executive Drive
Suite 325
San Diego, CA 92121
info@oncolyticsbiotech.com

Company

About Us
Leadership
Scientific Advisors
Careers
Contact

Science

Our Science
Pipeline
Publications

Investors

Overview
News
Events
Stock Information
Filings
Corporate Governance
FAQs

Privacy Policy Accessibility Cookie Policy Disclaimer Sitemap Manage Consent

Copyright © 2025 Oncolytics Biotech Inc.